Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Efficacy of Ovarian Drilling Via vNOTES Laparoscopy in Patients With PCOS (DRINOTES)

2 de noviembre de 2026 actualizado por: University Hospital, Clermont-Ferrand

Proof-of-Concept Study Evaluating the Efficacy of Ovarian Drilling Via vNOTES Laparoscopy in Patients With PCOS Requiring Surgical Treatment.

Polycystic Ovary Syndrome (PCOS) is a common condition among young women (the leading endocrine disorder) and is responsible for 70% of anovulatory infertility cases. Clinically, it has been defined since 2003 by the Rotterdam criteria, according to the French College of Obstetricians and Gynecologists. PCOS represents a significant challenge in reproductive medicine, as it is associated with infertility rates ranging from 20% to 74%. Ovarian stimulation is the first-line treatment for PCOS, as no etiological treatment is available. The first-line pharmacological treatment is Clomiphene Citrate. In cases where Clomiphene Citrate fails, the second-line treatment is ovarian drilling. Traditionally, ovarian drilling was performed via laparoscopy or fertiloscopy. Fertiloscopy had the advantage of being quicker and scarless for patients, with reported failure and conversion rates to laparoscopy of 10% to 20% depending on the studies. However, fertiloscopy is no longer practiced due to the discontinuation of the device. With the advent of vNOTES laparoscopy (Vaginal Natural Orifice Transluminal Endoscopic Surgery) in the 2010s for benign gynecological conditions, the possibility of a new vaginal approach for ovarian drilling is now being considered. The Primary Objective is to Evaluate the efficacy of ovarian drilling via vNOTES laparoscopy in terms of resumption of spontaneous ovulatory cycles in PCOS patients requiring surgical treatment.

Study Type:

Single-center, randomized, controlled, two-arm, proof-of-concept study. Number of Centers: 1

Study Description:

During the gynecology consultation, if an indication for ovarian drilling is established, the patient will be invited to participate in the study protocol. The study information sheet, detailing the study procedures and objectives, along with the consent form, will be provided to the patient.

A second consultation with the investigator will be scheduled to address any questions following a reflection period. If the patient consents, both she and the investigator will sign the consent form.

Randomization will be conducted using REDCap® software. The patient will then be assigned to either the vNOTES group or the laparoscopy group. Surgery will be performed by surgeons designated as "experts" in the respective surgical approach. The procedure will follow the standard techniques of the department.

Ovulatory cycle resumption will be assessed 6 months postoperatively during a follow-up consultation.

Descripción general del estudio

Descripción detallada

Latest State of Scientific Knowledge Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in young women (5% of women of reproductive age) and is responsible for 70% of anovulatory infertility cases.

Since 2003, it has been defined according to the College of Obstetricians and Gynecologists of France by the Rotterdam criteria, which were revised by ESHRE in 2023.

According to these criteria, to diagnose PCOS, it is necessary to present at least two of the following three criteria and to have excluded other diagnoses:

Menstrual cycle abnormalities (amenorrhea, oligomenorrhea, long cycles) Clinical (hirsutism, acne, hair loss) or biological hyperandrogenism (elevated levels of free and total testosterone) Presence of polycystic ovaries on ultrasound: at least 12 follicles measuring 2 to 9 mm in diameter in each ovary or more than 20 follicles regardless of size. The number of follicles is more relevant than ovarian volume .

PCOS is a significant concern for reproductive medicine as it is associated with 20% to 74% infertility due to arrested follicular maturation caused by a multifactorial mechanism, particularly involving hyperandrogenism caused by excessive androgen production by the ovarian theca cells.

Ovarian stimulation is the first-line treatment for infertility related to PCOS as there is no etiological treatment. The first-line treatment is Clomiphene Citrate. It is a SERM that acts by inhibiting the negative feedback of estrogens on FSH. In case of failure, second-line treatment is ovarian drilling or gonadotropin stimulation according to ESHRE 2018 recommendations. Ovarian drilling involves making perforations in the ovarian stroma to destroy approximately 5% of the cortex of each ovary. It is recommended to use bipolar energy rather than monopolar or CO2 laser energy to reduce the risk of adhesions. Moreover, bipolar energy decreases the diffusion of energy compared to monopolar, thus limiting the reduction of the ovarian follicle pool. Although the mechanism remains unclear, it appears that the destruction of ovarian stroma by microperforations reduces androgen levels, increases FSH levels, and promotes follicular maturation.

The first ovarian drilling by laparoscopy was described in 1984 by Gjonnaess and his team. It was traditionally performed via laparoscopy or fertiloscopy. The latter technique is no longer practiced due to the discontinuation of the device.

More recently, in the 2010s, a new minimally invasive laparoscopic technique, vNOTES (Vaginal Natural Orifice Transluminal Endoscopic Surgery), was developed, using a natural orifice: the vagina. This method was first developed in Taiwan in 2012, then in Belgium.

With the development of the vNOTES laparoscopic technique for benign gynecological pathologies, particularly adnexal pathologies, the question arises of a new approach for ovarian drilling. Indeed, data on its use in the context of ovarian drilling are very limited, but initial results show a minimally invasive approach with good access to the pelvic cavity, minimal scarring, and reduced postoperative pain . The ovarian drilling technique using vNOTES was recently described by Professor Fernandez and his team and presented in a video at the SCGP congress in 2022 .

Hypotheses and Objectives The study is based on the hypothesis that ovarian drilling via vaginal vNOTES laparoscopy is at least as effective as the conventional laparoscopic technique in terms of resumption of ovulatory cycles. The objective is to evaluate the effectiveness of vaginal vNOTES laparoscopy compared to abdominal laparoscopy for ovarian drilling in women with polycystic ovary syndrome undergoing medically assisted reproduction.

Summary of Expected Benefits and Risks for Participants Expected benefits for patients in the VNotes group: shorter operative duration, less significant pain evolution, and aesthetic benefits.

Risks: The risks are those associated with anesthesia and surgery: hemorrhage, infection, digestive, vascular, or urinary tract injury, vaginal scar dehiscence. The additional risks of laparoscopy are those associated with trocars: hemorrhage, infection, herniation, and scar dehiscence.

The additional risk of vNOTES is the inability to complete the procedure, requiring conversion to laparoscopy.

Expected Outcomes If the ovarian drilling technique via VNotes proves to be as effective as laparoscopy, it would legitimize the development of an innovative technique combining good anatomical visualization, absence of abdominal scarring, and better outcomes in the context of assisted reproduction, as well as improved postoperative recovery for patients, with equivalent results in terms of ovulation resumption and pregnancy.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

48

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 43 años (Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • PCOS defined by Rotterdam criteria requiring ovarian drilling after failure of first-line medical treatment
  • Primary or secondary infertility
  • Able to provide informed consent to participate in the research

Exclusion Criteria:

  • History of ovarian drilling
  • History of multiple pelvic surgeries
  • Current pregnancy or breastfeeding
  • Need for another associated surgical procedure other than hysteroscopy (hysteroscopy, neostomy)
  • Other infertility factors requiring IVF management
  • Contraindication to either surgical approach (laparoscopy or vNOTES):
  • History of upper genital tract infection
  • Confirmed or suspected recto-vaginal endometriosis on clinical examination
  • History of rectal surgery
  • Promontofixation
  • Virgin patient
  • Any concomitant pathology deemed incompatible with the study
  • Patients not affiliated with the social security system
  • Patients not speaking French
  • Patients under guardianship, curatorship, deprived of liberty, or under judicial protection
  • Refusal to participate

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: ovarian drilling by abdominal laparoscopy

Ovarian drilling procedure by abdominal laparoscopy

1st stage of surgery Patient in gynecological position, double skin cleansing with alcoholic Betadine and vaginal cleansing with dermal Betadine, placement of sterile drapes.

Urinary evacuation catheterization. Introduction of a diagnostic hysteroscope via vaginoscopy. Progress through the cervical canal. Exploration of the uterine cavity. Cannulation using a manipulator to perform a tubal blue test. 2nd stage of surgery: Patient in supine position, legs slightly abducted and semi-flexed. Insufflation of pneumoperitoneum in left hypochondrium with Palmer needle after satisfactory syringe safety test, up to a pressure of 20 mmHg. Trans-umbilical coeliotomy allowing passage of a 10 mm optical trocar after infiltration of the tract with Naropein 7.5 mg/ml.

Placement of two 5 mm operating trocars in the left iliac fossa and suprapubic area after infiltration of the tracts with Naropein 7.5 mg/ml.

Single-stitch closure with Filapeau 3/0.

Ovarian drilling procedure by abdominal laparoscopy versus ovarian drilling procedure by laparoscopic Vnotes .

see each arm for details for each intervention

Experimental: Ovarian drilling by vaginal laparoscopy VNotes

Patient in gynecological position, double scrubbing of skin with alcoholic Betadine and vaginal with dermal Betadine, sterile drapes in place Urinary evacuation catheterization Introduction of a diagnostic hysteroscope via vaginoscopy Progress through the cervical canal Exploration of the uterine cavity Para-cervical block, uterine cannulation using a manipulator or a pediatric foley probe to perform a tubal blue test.

Placement of a Pozzi on the posterior lip of the cervix. Vaginal incision 1 cm below the cervix for 2 cm, opening the peritoneum with scissors vNOTES Gelpoint device inserted Trendelenburg position Insufflation of pneumoperitoneum(8 mm Hg) Exploration of abdominal cavity Bilateral ovarian drilling; approx. 12 to 15 micro-perforations on each side using the bipolar Versapoint inserted in the Bettochi and regular saline instillation Systematic tubal blue test Removal of the device Exsufflation of pneumoperitoneum Closure of the cul de sac of Douglas with a MONOCRYL 2/0

Ovarian drilling by vaginal laparoscopy VNotes

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
The resumption (or not) of an ovulatory cycle
Periodo de tiempo: at the 6 months follow-up visit

The resumption (or not) of an ovulatory cycle will be evaluated during the 6 months follow-up visit after the intervention. The resumption of cycles is defined by cycles lasting more than 3 months, an elevated progesterone level, or the presence of a corpus luteum on ultrasound."

at the 6 months follow-up visit

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Pain assessment
Periodo de tiempo: 1 hour during ambulatory care

For each arm: Pain assessment using a VAS (Visual Analog Scale) requested from the patient in the recovery room at 1 hour during ambulatory care. The scale ranges from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable

1 hour during ambulatory care
pain assessment
Periodo de tiempo: 6 hours during ambulatory care

For each arm: Pain assessment using a VAS (Visual Analog Scale) requested from the patient in the recovery room at 6 hours during ambulatory care. The scale ranges from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable

6 hours during ambulatory care
pain assessment
Periodo de tiempo: on day 1 after the intervention

For each arm: Pain assessment using a VAS (Visual Analog Scale) requested from the patient through a questionnaire sent to the patients on Day 1 after the intervention. The scale ranges from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable

on day 1 after the intervention
pain assessment
Periodo de tiempo: on day 7 after the intervention

For each arm: Pain assessment using a VAS (Visual Analog Scale) requested from the patient on Day 7 after the intervention. The scale ranges from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable

on day 7 after the intervention
pain assessment
Periodo de tiempo: at the postoperative follow-up visit (1 month)

For each arm: Pain assessment using a VAS (Visual Analog Scale) requested from the patient during the postoperative follow-up visit. The scale ranges from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable

at the postoperative follow-up visit (1 month)
The use of analgesics
Periodo de tiempo: up to 2 hours postoperatively

For each arm: The use of analgesics (yes/no) recorded up to 2 hours postoperatively

up to 2 hours postoperatively
The use of analgesics
Periodo de tiempo: up to 24 hours postoperatively

For each arm: The use of analgesics (yes/no) recorded up to 24 hours postoperatively

up to 24 hours postoperatively
The use of analgesics
Periodo de tiempo: postoperatively on Day 1

For each arm: The use of analgesics (yes/no) recorded postoperatively through a questionnaire sent to the patients on Day 1.

postoperatively on Day 1
The use of analgesics
Periodo de tiempo: postoperatively on Day 7

For each arm: The use of analgesics (yes/no) recorded postoperatively through a questionnaire sent to the patients on day 7

postoperatively on Day 7
The use of analgesics
Periodo de tiempo: at the postoperative follow-up visit (1 month)

For each arm: The use of analgesics (yes/no) recorded at the postoperative follow-up visit (1 month)

at the postoperative follow-up visit (1 month)
The operative duration
Periodo de tiempo: peroperatively

For each arm: The operative duration from incision to closure recorded in the operating room, as well as the operative duration from the introduction of the Palmer needle in laparoscopy and the vaginal incision in VNotes until closure

peroperatively
Rehospitalization due to complications
Periodo de tiempo: at the postoperative follow-up visit (1 month)

for each arm: Rehospitalization due to complications from the operation within the month following the procedure (yes/no), at the postoperative follow-up visit (1 month)

at the postoperative follow-up visit (1 month)
Extension of the initial sick leave (yes/no)
Periodo de tiempo: at the postoperative follow-up visit (1 month)

For each arm: Extension of the initial sick leave (yes/no), assessed at the postoperative follow-up visit (1 month)

at the postoperative follow-up visit (1 month)
The presence of intraoperative complications
Periodo de tiempo: during the intervention

for each arm: The presence of intraoperative complications recorded during the intervention according to the Clavien-Dindo classification, including whether a conversion occurred, and the number of such complications

during the intervention
extension of the ambulatory stay (yes/no)
Periodo de tiempo: Upon discharge from hospitalization (assessed up to 5 days)

For each arm: The use of an extension of the ambulatory stay (yes/no) and the total duration of hospitalization in days and hours

Upon discharge from hospitalization (assessed up to 5 days)
The occurrence of a pregnancy
Periodo de tiempo: one year after the 6 months follow-up visit

The occurrence of a spontaneous pregnancy, IVF, twin pregnancy, or OHSS if IVF, assessed one year after the 6 months follow-up visit

one year after the 6 months follow-up visit
The measurement of AMH
Periodo de tiempo: at the preoperative visit (1 month before the intervention)

The measurement of AMH in nanograms/mL at the preoperative visit (1 month before the intervention)

at the preoperative visit (1 month before the intervention)
The measurement of AMH
Periodo de tiempo: at the postoperative follow-up visit (1 month)

The measurement of AMH in nanograms/mL at the postoperative follow-up visit (1month).

at the postoperative follow-up visit (1 month)
The measurement of AMH
Periodo de tiempo: at the 6 Months follow-up visit

The measurement of AMH in nanograms/mL at the Month 6 follow-up visit

at the 6 Months follow-up visit
Satisfaction assessment
Periodo de tiempo: at the postoperative follow-up visit (1 month)

Satisfaction assessment through the SF-36 questionnaire at the postoperative follow-up visit

at the postoperative follow-up visit (1 month)
Satisfaction assessment
Periodo de tiempo: at the 6 Months follow-up visit

Satisfaction assessment through the SF-36 questionnaire at the 6 Months follow-up visit

at the 6 Months follow-up visit

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Anne-Sophie Gremeau, University Hospital, Clermont-Ferrand

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

14 de marzo de 2025

Finalización primaria (Estimado)

14 de septiembre de 2030

Finalización del estudio (Estimado)

14 de septiembre de 2030

Fechas de registro del estudio

Enviado por primera vez

19 de septiembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Publicado por primera vez (Actual)

6 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de abril de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir